Anebulo Pharmaceuticals (FRA:214) Common Stock: €0.04 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:214 Anebulo Pharmaceuticals Inc FRA:214
35 GF Score
Price €0.75
! 1 Warning Sign
View Full Analysis

What is Anebulo Pharmaceuticals Common Stock?

Anebulo Pharmaceuticals FRA:214 35 Common Stock is €0.04 Mil as of Dec. 2025. GuruFocus rates FRA:214 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Anebulo Pharmaceuticals's quarterly common stock declined from Jun. 2025 (€0.04 Mil) to Sep. 2025 (€0.04 Mil) but then stayed the same from Sep. 2025 (€0.04 Mil) to Dec. 2025 (€0.04 Mil).

Anebulo Pharmaceuticals's annual common stock stayed the same from Jun. 2023 (€0.02 Mil) to Jun. 2024 (€0.02 Mil) but then increased from Jun. 2024 (€0.02 Mil) to Jun. 2025 (€0.04 Mil).

Anebulo Pharmaceuticals Common Stock Historical Data

* Premium members only.

The historical data trend for Anebulo Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anebulo Pharmaceuticals Common Stock Chart

Anebulo Pharmaceuticals Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Common Stock
Get a 7-Day Free Trial 0.02 0.02 0.02 0.02 0.04

Anebulo Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.04 0.04 0.04
FRA:214
35GF Score
Anebulo Pharmaceuticals Inc FRA:214
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anebulo Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €0.04 Mil mean?
Anebulo Pharmaceuticals (FRA:214) has a Common Stock of €0.04 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Anebulo Pharmaceuticals and its competitors.
Is Anebulo Pharmaceuticals' Common Stock too high?
Anebulo Pharmaceuticals' current Common Stock is €0.04 Mil. Overall, Anebulo Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Anebulo Pharmaceuticals' Common Stock compare to PHIO and COCP?
Anebulo Pharmaceuticals' Common Stock of €0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Anebulo Pharmaceuticals and its competitors. Anebulo Pharmaceuticals's current Common Stock is €0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anebulo Pharmaceuticals stock overvalued right now?
Anebulo Pharmaceuticals (FRA:214) has a current Common Stock of €0.04 Mil. The current Common Stock is €0.04 Mil. Anebulo Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Anebulo Pharmaceuticals (FRA:214), the current Common Stock is €0.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anebulo Pharmaceuticals Business Description

Other Exchanges ANEB:USA
Address 1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
35GF Score

Get the complete analysis for FRA:214

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.75
Price